Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 1 2Phase NA 1Phase 1/2 1

Status

Recruiting 2Completed 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Tumor-Agnostic 1Sarcoma 1

Conditions

Breast Neoplasms 163Endometrial Neoplasms 13Ovarian Neoplasms 12Fallopian Tube Neoplasms 5Recurrence 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Intraductal, Noninfiltrating 4Triple Negative Breast Neoplasms 3Breast Diseases 3Breast Cancer Metastatic 3Prostatic Neoplasms 2Leiomyosarcoma 2Carcinoma, Lobular 2Advanced Breast Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Polycystic Ovary Syndrome 1Pathologic Complete Response 1Pancreatic Neoplasms 1Pain 1Osteoporosis 1Neoplastic Cells, Circulating 1Neoadjuvant Operable Breast Cancer 1Multiple Endocrine Neoplasia Type 1 1Medullary cystic kidney disease 1 1Lymphangioleiomyomatosis 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Letrozole × Clear all
NCT06979596 2026-05-13

OMAHA-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
250 enrolled
Tumor-Agnostic

Neoplasms

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01684215 2020-11-23

A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer

Pfizer

Phase 2 Completed
61 enrolled 45 charts
Breast

Breast Neoplasms, Neoplasms

NCT00062751 2011-04-15

Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 2 Completed
108 enrolled 4 charts
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡